Prostate cancer drug approved for routine use before chemotherapy

CRUK. 21 March 2016

Image shows false-coloured scanning electron micrograph of a single prostate cancer cell grown in culture

The National Institute for Health and Care Excellence (NICE) has approvedthe drug abiraterone for men with advanced prostate cancer, who have not yet had chemotherapy.  The drug – developed by UK scientists – can delay the disease’s progression, help to prolong life, and provide a better quality of life with less fatigue and pain. It has been available across the UK for men after chemotherapy since 2012.

Today’s decision – a reversal of NICE’s previous ruling – brings England and Wales in line with Scotland, which approved(link is external) the drug for men pre-chemotherapy last year. NICE was able to rule favourably after the drug’s manufacturers, Janssen, provided new data showing the drug’s cost-effectiveness, and agreed a discount price for the NHS.

Under the discount, the NHS will pay for the first 10 months of treatment. For people who remain on treatment for more than 10 months, Janssen will cover the drug’s cost from the 11th month until the end of treatment.

Until now, the drug was only available to patients in England before chemotherapy through the Cancer Drugs Fund (CDF), and was the second most requested medicine on the fund. Today’s approval means that drug can now also been removed from the Fund – which is the process of being reformed – and paid for routinely by the NHS.

Read the full commentary here

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s